50 results
8-K
EX-99.2
AXLA
Axcella Health Inc.
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
Vascular System and Leads to Chronic Inflammation in Long Covid Building on a Foundation of AXA1125 Multi - Targeted Activity Vascular environment … and data to study its potential in Long Covid
© 2022 Axcella Therapeutics. All rights reserved. 35 AXA1125 Targets Key Environment, Inflammation
DEFA14A
AXLA
Axcella Health Inc.
7 Apr 22
Additional proxy soliciting materials
4:00pm
Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future
DEFA14A
AXLA
Axcella Health Inc.
3 Apr 20
Additional proxy soliciting materials
4:19pm
for your delivery preferences. Vote your shares. When you go online, you can also help the environment by consenting to receive electronic delivery
DEFA14A
AXLA
Axcella Health Inc.
5 Apr 21
Additional proxy soliciting materials
4:18pm
go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Copy of the Proxy Materials
8-K
EX-99.1
AXLA
Axcella Health Inc.
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
understanding of the benefits AXA1125 delivers to Long COVID patients. Preliminary analysis including mitochondrial, inflammatory, and endothelial environment
8-K
EX-10.1
9m63v2
23 Sep 22
Entry into a Material Definitive Agreement
4:01pm
10-Q
gsosa f49
20 Jun 19
Quarterly report
5:03pm